IDEAYA Biosciences, Inc.
darovasertib
metastatic uveal melanoma
Resolved
85days ago
Phase 3 readout · Apr 13, 2026
What's at stake
Phase 3 trial results for darovasertib in metastatic uveal melanoma are due Apr 13, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“On April 13, 2026, IDEAYA Biosciences, Inc. (the “Company”) and Servier ... announced clinical data from the Company’s Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib...”